The Liebowitz social anxiety scale as a self-report instrument: a preliminary psychometric analysis

Baker, Sandra L.; Heinrichs, Nina; Kim, Hyojin; Hofmann, S.

doi:10.1016/s0005-7967(01)00060-2

Cited by 526 publications

(426 citation statements)

References 34 publications

Supporting

Mentioning

379

Contrasting

Unclassified

Order By: Relevance

“…It can be either researcher-administered or self-rated, both of which have proven psychometric support (Baker, Heinrichs, Kim & Hofmann, 2002;Heimberg et al, 1999;Oakman, Van Ameringen, Mancini & Farvolden, 2003). We used the self-rating format in the present study.…”

Section: Outcome Measuresmentioning

confidence: 99%

Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder

Book¹,

Thomas²,

Randall³

et al. 2008

Journal of Anxiety Disorders

View full text Add to dashboard Cite

Patients with social anxiety disorder who are seen in clinical practice commonly have additional psychiatric comorbidity, including alcohol use disorders. The first line treatment for social anxiety disorder is selective-serotonin-reuptake-inhibitors (SSRIs), such as paroxetine. However, the efficacy of SSRIs has been determined with studies that excluded alcoholics. Forty two subjects with social anxiety and a co-occurring alcohol use disorder participated in a 16-week, double-blind, placebo-controlled clinical trial to determine the efficacy of paroxetine for social anxiety in patients with co-occurring alcohol problems. Paroxetine was superior to placebo in reducing social anxiety, as measured by the Liebowitz Social Anxiety Scale total and subscale scores and additional measures of social anxiety. This study provides the first evidence-based recommendation for the use of an SSRI to treat social anxiety in this patient population.

show abstract

Section: Outcome Measuresmentioning

confidence: 99%

Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder

Book¹,

Thomas²,

Randall³

et al. 2008

Journal of Anxiety Disorders

View full text Add to dashboard Cite

show abstract

“…The clinician-administered scale is widely used in studies of pharmacological treatment of social phobia. A recent study using a large sample of individuals with social phobia examined the psychometric characteristics of the self-report version of the LSAS (Baker, Heinrichs, Kim, & Hofmann, 2002). The self-report version of the LSAS was highly correlated with the clinician version, with correlations between these versions ranging from .78 to .85, depending on the subscales.…”

Section: Assessmentsmentioning

confidence: 99%

Sudden gains during therapy of social phobia.

Hofmann

Schulz

Meuret

et al. 2006

Journal of Consulting and Clinical Psychology

104

109

View full text Add to dashboard Cite

The present study investigated the phenomenon of sudden gains in 107 participants with social phobia (social anxiety disorder) who received either cognitive-behavioral group therapy or exposure group therapy without explicit cognitive interventions, which primarily used public speaking situations as exposure tasks. Twenty-two out of 967 session-to-session intervals met criteria for sudden gains, which most frequently occurred in Session 5. Individuals with sudden gains showed similar improvements in the 2 treatment groups. Although cognitive-behavioral therapy was associated with more cognitive changes than exposure therapy, cognitive changes did not precede sudden gains. In general, the results of this study question the clinical significance of sudden gains in social phobia treatment.Keywords sudden gains; social anxiety disorder; social phobia; cognitive-behavioral therapy; exposure therapyIn recent years, psychotherapy researchers have investigated the phenomenon of large, rapid, and stable decreases in symptomatology during treatment, which has been referred to as sudden gains (Tang & DeRubeis, 1999b). Sudden gains are typically defined by a set of three quantitative criteria: (a) the sudden gain must be large in absolute terms, (b) the sudden gain must represent at least a 25% reduction from the level of symptomatology before the gain occurred, and (c) the mean level of symptomatology in the three therapy sessions preceding the gain must be significantly higher than the mean level of symptomatology in the three postgain sessions. Most studies of sudden gains have examined treatment changes in depression with the Beck Depression Inventory (BDI; Beck, Ward, Mendelson, Mock, & Erbaugh, 1961; but see also Stiles et al., 2003;Vittengl, Clark, & Jarrett, 2005).When applying these criteria, Tang and DeRubeis (1999b) found that sudden gains occurred in more than 50% of individuals who responded to cognitive-behavioral therapy for depression and that these gains accounted for more than 50% of these individuals' total improvement in depression. Compared with participants who did not experience sudden gains at posttreatment, individuals with sudden gains showed better outcome at posttreatment and at 6-month and 18-month follow-ups.The initial study by Tang and DeRubeis (1999b) was followed by a number of other studies examining sudden gains (Gaynor et al., 2003;Hardy et al., 2005;Kelly, Roberts, & Ciesla, 2005;Tang, DeRubeis, Beberman, & Pham, 2005;Tang, Luborsky, & Andrusyna, 2002;Vittengl, Clark, & Jarrett, 2005). Interventions in these studies ranged from traditional cognitive therapy to supportive expressive therapy or pharmacotherapy. Although sudden gains were primarily assessed in efficacy trials of time-limited individual treatments (e.g., Tang NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author Manuscript DeRubeis, 1999b;Vittengl et al., 2005), their incidence was also assessed in group therapy for depression (Kelly et al., 2005) and individuals with mixed psychiatric diagnoses who were g...

show abstract

“…[9,[11][12][13] There is also evidence that the clinician-administered version of the LSAS and LSAS-SR may be equivalent. For example, they are highly correlated, and there are no mean differences between them for patients with social anxiety disorder and nonanxious controls.…”

Section: Introductionmentioning

confidence: 99%

“…For example, they are highly correlated, and there are no mean differences between them for patients with social anxiety disorder and nonanxious controls. [9,11] However, although these two measures seem to function similarly, it is unclear whether the LSAS cut scores used to classify participants with social anxiety disorder and the generalized subtype of social anxiety disorder [10] also apply to the LSAS-SR. Thus, our goals were as follows:…”

Section: Introductionmentioning

confidence: 99%

Screening for social anxiety disorder with the self-report version of the Liebowitz Social Anxiety Scale

et al. 2009

View full text Add to dashboard Cite

The Liebowitz social anxiety scale as a self-report instrument: a preliminary psychometric analysis

Cited by 526 publications

References 34 publications

Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder

Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder

Sudden gains during therapy of social phobia.

Screening for social anxiety disorder with the self-report version of the Liebowitz Social Anxiety Scale

Contact Info

Product

Resources

About